Wird geladen...
Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain?
The brain is the most common site of first metastasis for patients with HER2-positive breast cancer treated with HER2-targeting drugs. However, the development of effective therapies for breast cancer brain metastases (BCBMs) is limited by an incomplete understanding of the mechanisms governing drug...
Gespeichert in:
| Veröffentlicht in: | Clin Cancer Res |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5899637/ https://ncbi.nlm.nih.gov/pubmed/29437794 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-3351 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|